Treatment
Dapagliflozin clinical trials
We’re tracking 92 recruiting studies that include Dapagliflozin, each written for real people, not researchers, below.
Recruiting studies
- NCT05374291Enrolling by invitationPhase 3
Dapagliflozin trial for kidney and heart outcomes in severe CKD
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
Canberra, Australian Capital TeritoryAges 18 years+ - NCT07056699RecruitingPhase 3
Study on diabetes drugs and ketone production in type 1 diabetes
This trial tests how two diabetes medications, SGLT2i and pioglitazone, affect ketone production in people with type 1 diabetes. It aims to find new ways to improve blood sugar control.
San Antonio, TexasAges 18 years+ - NCT07019012RecruitingPhase 4
Testing a new every-2-week pill for type 2 diabetes
This study tests a new once-every-2-weeks pill (cofrogliptin) added to your current diabetes medications (metformin and dapagliflozin) compared to a daily pill (linagliptin). It may help improve blood sugar control with fewer daily pills.
Wuhan, HubeiAges 18 years+ - NCT07147114RecruitingPhase 4
Combined macitentan and dapagliflozin for heart failure with lung high blood pressure
This trial tests whether adding two medications—macitentan and dapagliflozin—together is safe and effective for people with heart failure and a certain type of high blood pressure in the lungs. It might help improve your symptoms and daily function.
BusanAges 19 years+ - NCT07018622RecruitingPhase 2
Protecting kidneys from platinum chemotherapy damage
This trial tests a way to protect your kidneys while you receive platinum-based chemotherapy (cisplatin or carboplatin) for a solid tumor. It may help reduce the risk of kidney damage so you can complete your treatment more safely.
México, TlalpanAges 18 years+ - NCT06875193RecruitingPhase 4
Comparing dapagliflozin vs pioglitazone for type 2 diabetes
This study is testing two different diabetes pills—dapagliflozin or pioglitazone—in people with type 2 diabetes. The goal is to see which one works better when added to your current metformin and DPP-4 inhibitor. You may qualify if your blood sugar is not well controlled with your current medications.
SeoulAges 19 years+ - NCT05521984RecruitingPhase 1
Dapagliflozin trial for children with hard-to-treat brain tumors
This Phase 1 trial tests whether dapagliflozin (an SGLT2 medicine) can help shrink or control certain pediatric brain tumors or other solid tumors that have come back or won’t respond. It’s designed mainly to check safety and early signs of effect in children and young adults who have limited treatment options.
St Louis, MissouriAges 6–21 - NCT07662135RecruitingPhase 3
A study of elecoglipron for type 2 diabetes with kidney problems
This trial tests a new medicine called elecoglipron to see if it helps control blood sugar in people with type 2 diabetes who also have reduced kidney function. You would continue taking your current SGLT2i medication (like dapagliflozin).
Peoria, ArizonaAges 18 years+ - NCT06742723RecruitingPhase 3
Study of baxdrostat and dapagliflozin for kidney disease and high blood pressure
This trial tests if combining baxdrostat with dapagliflozin helps protect kidney function and reduce heart risks in people with chronic kidney disease and high blood pressure. It's for adults who are already taking standard blood pressure medications.
Fairhope, AlabamaAges 18 years+ - NCT02969798Recruiting
Study of prediabetes with abnormal sugars and medicines
This study looks at adults with prediabetes—specifically abnormal fasting and/or 2-hour blood sugar tests—to see whether a treatment helps improve sugar control. You may also be compared with people who have normal blood sugar (the control group).
San Antonio, TexasAges 18–65 - NCT04591639Recruiting
DAPA test for diabetes and heart failure using body scans
This study tests how a medication called DAPA (an SGLT2 inhibitor) affects the body in people with heart failure (with or without type 2 diabetes), or in some people with type 2 diabetes only. It may help researchers understand who could benefit most and what changes happen in the heart, using specialized heart imaging.
Edinburgh, ScotlandAges 18 years+ - NCT05345327RecruitingPhase 3
First diabetes pill to protect kidneys
This Phase 3 trial tests whether starting a diabetes medicine called dapagliflozin can better slow kidney damage than starting metformin in adults with type 2 diabetes. It may help preserve kidney function over time and reduce future kidney decline.
Sydney, New South WalesAges 18 years+ - NCT05852704RecruitingPhase 3
Dapagliflozin to prevent irregular heart rhythm after bypass surgery
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
BrnoAges 18 years+ - NCT05938712RecruitingPhase 2
Kidney transplant trial using two diabetes medicines safely
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
Toronto, OntarioAges 18 years+ - NCT05970237Recruiting
Dapagliflozin for type 2 diabetes with high blood pressure
This trial studies whether dapagliflozin (the medicine in Trudapa tabs) is safe and works in people who have both type 2 diabetes and high blood pressure. It may help control blood sugar and blood pressure, while researchers closely watch for side effects.
Incheon, Namdong-guAges 19 years+ - NCT06009874Recruiting
SGLT2 inhibitor early after heart attack to protect the heart
This study tests whether giving an SGLT2 inhibitor (a diabetes medicine that may also protect the heart) early after a heart attack can help shield the heart from damage. It is for people having a first-time STEMI heart attack who have adequate kidney function and stable blood pressure.
Shibīn al Kawm, MenofiaAges 18–80 - NCT06054035RecruitingPhase 4
SGLT2 inhibitor for prediabetes complications
This trial tests if a drug called dapagliflozin (an SGLT2 inhibitor) can help prevent complications in people with prediabetes when added to lifestyle changes. It aims to see if this approach works better than lifestyle changes alone.
BerlinAges 35–75 - NCT06155604RecruitingPhase 2
SGLT2 inhibitor for lupus nephritis with kidney disease
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
Hong KongAges 18 years+ - NCT06364930RecruitingPhase 4
SGLT2 inhibitor to prevent liver problems in hepatitis B and diabetes
This study tests if adding a diabetes medicine called an SGLT2 inhibitor to your current treatment can help prevent liver complications in people with chronic hepatitis B and type 2 diabetes or prediabetes. If you have early liver scarring and stable diabetes treatment, this could offer extra protection for your liver.
Hong KongAges 18 years+ - NCT06491680RecruitingPhase 4
Heart safety during breast cancer chemo
This trial checks how well the heart handles anthracycline chemotherapy in breast cancer patients. It helps doctors find early signs of heart side effects so they can keep you safe during treatment.
Cairo, Cairo GovernorateAges 18–60 - NCT06528405RecruitingPhase 2
SGLT2 inhibitor study for acute kidney disease patients
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
TaipeiAges 18–80 - NCT06562582RecruitingPhase 4
Starting heart drugs after a STEMI heart attack
This study tests whether starting a beta blocker and an SGLT2 inhibitor right after a heart attack can help preserve heart function. It is for STEMI patients who have not yet been treated with these medicines.
GothenburgAges 18 years+ - NCT06572215Recruiting
New ways to check kidney function in sickle cell patients
This study tests two new methods to measure how well your kidneys can handle extra work, called kidney reserve. It might help find early signs of kidney problems in people with sickle cell disease or those who have donated a kidney.
LondonAges 40 years+ - NCT06642623RecruitingPhase 4
Study on heart and kidney health in type 2 diabetes
This trial tests enavogliflozin (a newer SGLT2 inhibitor) compared to older drugs (dapagliflozin or empagliflozin) to see how well it protects the heart and kidneys in people with type 2 diabetes.
SeoulAges 19 years+
Common questions
- Are there clinical trials studying Dapagliflozin?
- Yes. Clin2 currently lists 92 recruiting studies that include Dapagliflozin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dapagliflozin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dapagliflozin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dapagliflozin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.